Skip to main content
KOREA PHARMA Co., Ltd. logo

KOREA PHARMA Co., Ltd. — Investor Relations & Filings

Ticker · 032300 ISIN · KR7032300006 KO Manufacturing
Open in API
Filings indexed 175 across all filing types
Latest filing 2026-05-20 Capital/Financing Update
Country KR South Korea
Listing KO 032300

About KOREA PHARMA Co., Ltd.

https://www.koreapharma.co.kr/eng/main/…

KOREA PHARMA Co., Ltd. is a pharmaceutical company established in 1974 that specializes in the development and production of prescription-based medicines. The company has a particular focus on drugs for the Central Nervous System (CNS). Its product portfolio covers a wide range of therapeutic areas, including hepatic, gastrointestinal, antimicrobial, and antihistamine drugs. The company also offers treatments such as amino acids, antibiotics, antidotes, and antiepileptics, aiming to improve and maintain public health through its specialized pharmaceutical products.

Recent filings

Filing Released Lang Actions
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 90% confidence The document is a ‘주요사항보고서(전환사채권 발행결정)’ submitted to the Korean Financial Supervisory Service and Korea Exchange announcing the issuance of convertible bonds (CBs). It provides full terms of the bond issuance (amount, interest, maturity, conversion terms, put/call options, targeted investors, use of proceeds, etc.). This is a material financing update and not merely a summary or call transcript or board change notice. Under our taxonomy, an announcement of fundraising or capital structure change (debt or convertible debt issuance) falls squarely under Capital/Financing Update (CAP).
2026-05-20 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a detailed quarterly report (“분기보고서”) covering the period January 1, 2026 to March 31, 2026, containing extensive business overview, financial data, production figures, and segment results. It is not a brief release or an announcement of a report but the full interim/quarterly filing itself. Hence, it fits the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 93% confidence The document is a ‘주식등의 대량보유상황보고서’ (Report on Holdings of a Large Number of Shares) filed under Korean capital markets law, detailing the number and percentage of shares held by a major shareholder and related parties, changes in holdings, and related contracts. This aligns with a Major Shareholding Notification rather than a financial report or other announcement.
2026-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 93% confidence The document is a detailed ‘주식등의 대량보유상황보고서’ disclosing share ownership levels, percentages, related parties, and reasons for change under Korea’s Capital Markets Act. It is not an earnings release, annual report, or proxy statement, nor a management or legal report. It matches the definition of a Major Shareholding Notification (reporting threshold-crossing changes in significant ownership).
2026-04-03 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is the formal results of the Annual General Meeting (‘정기주주총회 결과’), listing each agenda item, whether it passed (‘가결’), and detailed voting percentages. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2026-03-27 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Korea Pharma (주식회사 한국파마) covering the fiscal years 2024 and 2025. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. While it contains financial data, it is specifically the formal audit report required by regulatory standards, not a standalone annual report (10-K) or a simple earnings release. Therefore, it is classified as an Audit Report. FY 2025
2026-03-19 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.